MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
592
Employees592
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
592
Employees592

MNKD Key Statistics

Market cap
1.21B
Market cap1.21B
Price-Earnings ratio
-26.46
Price-Earnings ratio-26.46
Dividend yield
Dividend yield
Average volume
3.17M
Average volume3.17M
High today
$3.75
High today$3.75
Low today
$3.74
Low today$3.74
Open price
$3.76
Open price$3.76
Volume
659.00
Volume659.00
52 Week high
$6.51
52 Week high$6.51
52 Week low
$2.23
52 Week low$2.23

Stock Snapshot

The current MannKind(MNKD) stock price is $3.74, with a market capitalization of 1.21B. The stock trades at a price-to-earnings (P/E) ratio of -26.46.

On 2026-09-15, MannKind(MNKD) stock moved within a range of $3.74 to $3.75. With shares now at $3.74, the stock is trading 0.0% above its intraday low and -0.3% below the session's peak.

Trading volume for MannKind(MNKD) stock has reached 659, versus its average volume of 3.17M.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

MNKD News

Simply Wall St 4d
MannKind Stock May Be 15% Undervalued After Inhaled GLP 1 Deal - simplywall.st

...

MannKind Stock May Be 15% Undervalued After Inhaled GLP 1 Deal - simplywall.st
Seeking Alpha 6d
MannKind, Rose Pharma team up for inhaled GLP-1 therapy

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from pr...

MannKind, Rose Pharma team up for inhaled GLP-1 therapy
TipRanks 6d
MannKind and Rose Pharma sign licensing and collaboration agreement

MannKind (MNKD) and Rose Pharma announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for wei...

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.